Frontiers in Oncology 2018 April [Link] Rossini M, Rizzo P, Bononi I, Clementz A, Ferrari R, Martini F, Tognon MG Abstract Malignant pleural mesothelioma (MPM) is a rare, but severe form of cancer, with an incidence that varies significantly within and among different countries around the world. It develops in about one to two persons…

Read More

Journal of Cellular and Molecular Medicine 2018 March 24 [Epub ahead of print] [Link] Hsu PC, et. al. Abstract Although tumour PD-L1 (CD274) expression had been used as a predictive biomarker in checkpoint immunotherapy targeting the PD1/PD-L1 axis in various cancers, the regulation of PD-L1 (CD274) expression is unclear. Yes-associated protein (YAP), an important oncogenic…

Read More

International Journal of Molecular Sciences 2018 February [Link] Martínez-Rivera V, Negrete-García MC, Ávila-Moreno F, Ortiz-Quintero B Abstract Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor that originates in the pleura, is diagnosed in advanced stages and has a poor prognosis. Accurate diagnosis of MPM is often difficult and complex, and the gold standard…

Read More

BMC Research Notes 2017 November [Link] Winata P, Williams M McGowan E, Nassif N, van Zandwijk N, Reid G Abstract OBJECTIVE: MicroRNAs are frequently downregulated in cancer, and restoring expression has tumour suppressive activity in tumour cells. Our recent phase I clinical trial investigated microRNA-based therapy in patients with malignant pleural mesothelioma. Treatment with TargomiRs,…

Read More

Journal of Thoracic Oncology 2017 November 4 [Epub ahead of print] [Link] Johnson TG, et. al., Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive malignancy linked to asbestos exposure. On a genomic level, MPM is characterised by frequent chromosomal deletions of tumour suppressors, including microRNAs. MiR-137 plays a tumour suppressor role in other cancers,…

Read More

Molecular Oncology 2017 November 1 [Epub ahead of print] [Link] Schelch K, Kirschner MB, Williams M, Cheng YY, van Zandwijk N, Grusch M, Reid G Abstract Malignant pleural mesothelioma (MPM) is an aggressive malignancy with very limited therapeutic options. Fibroblast growth factor (FGF) signals play important roles in mesothelioma cell growth. Several FGFs and FGF…

Read More

Annals of Clinical Biochemistry 2017 January [Epub ahead of print] [Link] Arnold DT, Maskell N Abstract Mesothelioma is an aggressive cancer of pleural and peritoneal cells that is difficult to diagnose and monitor. Numerous studies have attempted to identify a blood- or pleural fluid-based biomarker that could be used in the diagnostic pathway. More recently…

Read More

Oncotarget 2017 August [Link] Truini A, et.al. Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor with a dismal overall survival (OS) and to date no molecular markers are available to guide patient management. This study aimed to identify a prognostic miRNA signature in MPM patients who did not undergo tumor resection. Whole miRNA profiling…

Read More